[go: up one dir, main page]

HUE054074T2 - Tökéletesített, új maytansinoidokat tartalmazó citotoxikus szerek - Google Patents

Tökéletesített, új maytansinoidokat tartalmazó citotoxikus szerek

Info

Publication number
HUE054074T2
HUE054074T2 HUE19160750A HUE19160750A HUE054074T2 HU E054074 T2 HUE054074 T2 HU E054074T2 HU E19160750 A HUE19160750 A HU E19160750A HU E19160750 A HUE19160750 A HU E19160750A HU E054074 T2 HUE054074 T2 HU E054074T2
Authority
HU
Hungary
Prior art keywords
cytotoxic agents
improved cytotoxic
new maytansinoids
maytansinoids
new
Prior art date
Application number
HUE19160750A
Other languages
English (en)
Inventor
Ravi V J Chari
Wayne C Widdison
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE054074(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of HUE054074T2 publication Critical patent/HUE054074T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
HUE19160750A 2003-05-20 2004-05-20 Tökéletesített, új maytansinoidokat tartalmazó citotoxikus szerek HUE054074T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47173903P 2003-05-20 2003-05-20

Publications (1)

Publication Number Publication Date
HUE054074T2 true HUE054074T2 (hu) 2021-08-30

Family

ID=33476883

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE04750945A HUE028314T2 (hu) 2003-05-20 2004-05-20 Javított citotoxikus szerek, amelyek tartalmaznak maytansinoidokat
HUE19160750A HUE054074T2 (hu) 2003-05-20 2004-05-20 Tökéletesített, új maytansinoidokat tartalmazó citotoxikus szerek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE04750945A HUE028314T2 (hu) 2003-05-20 2004-05-20 Javított citotoxikus szerek, amelyek tartalmaznak maytansinoidokat

Country Status (28)

Country Link
EP (4) EP3524611B1 (hu)
JP (2) JP5208420B2 (hu)
KR (1) KR101145506B1 (hu)
CN (2) CN1956722A (hu)
AU (1) AU2004240541B2 (hu)
BR (2) BRPI0419348B8 (hu)
CA (1) CA2525130C (hu)
CL (1) CL2012000651A1 (hu)
CO (1) CO5660276A2 (hu)
CR (1) CR20170291A (hu)
CY (2) CY1117161T1 (hu)
DK (2) DK3524611T3 (hu)
EA (1) EA010909B1 (hu)
EC (1) ECSP056149A (hu)
ES (2) ES2863498T3 (hu)
HK (1) HK1116777A1 (hu)
HR (2) HRP20160046T1 (hu)
HU (2) HUE028314T2 (hu)
IL (6) IL171170A (hu)
LT (1) LT3524611T (hu)
MX (3) MX340862B (hu)
NO (1) NO339597B1 (hu)
NZ (1) NZ542695A (hu)
PL (2) PL1651162T3 (hu)
PT (2) PT1651162E (hu)
SI (2) SI3524611T1 (hu)
WO (1) WO2004103272A2 (hu)
ZA (1) ZA200507845B (hu)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004240541B2 (en) * 2003-05-20 2009-08-20 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
US8603483B2 (en) 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
EP2468304A3 (en) * 2005-02-11 2012-09-26 ImmunoGen, Inc. Process for preparing stable drug conjugates
JP2008535857A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌の診断、検出および処置におけるｃａｃｎａ１ｅ
AU2006235258A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes
EA200702239A1 (ru) 2005-04-15 2008-10-30 Иммьюноджен, Инк. Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
NZ716641A (en) * 2005-08-24 2017-06-30 Immunogen Inc Process for preparing maytansinoid antibody conjugates
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
PT1813614E (pt) 2006-01-25 2012-01-09 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina
EP2004221A2 (en) 2006-03-23 2008-12-24 Novartis Pharma AG Anti-tumor cell antigen antibody therapeutics
MX2008013121A (es) 2006-04-13 2009-03-25 Novartis Vaccines & Diagnostic Metodo para tratar, diagnosticar o detectar cancer.
JP2010521180A (ja) 2007-03-14 2010-06-24 ノバルティス アーゲー 癌を処置、診断または検出するためのａｐｃｄｄ１阻害剤
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
JP2013506709A (ja) * 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
PT2488873E (pt) 2009-10-16 2015-11-19 Novartis Ag Biomarcadores da resposta farmacodinâmica de tumores
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
CN105585630B (zh) 2010-07-29 2020-09-15 Xencor公司 具有修改的等电点的抗体
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
EA201390642A1 (ru) * 2010-11-03 2013-12-30 Иммуноджен, Инк. Цитотоксические агенты, содержащие новые производные анзамитоцина
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
RS58367B1 (sr) 2011-03-29 2019-03-29 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
EP2550975A1 (en) * 2011-07-29 2013-01-30 Sanofi Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
CA2851534C (en) 2011-10-10 2023-02-14 Xencor, Inc. A method for purifying antibodies
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
SI2900676T1 (sl) 2012-09-26 2019-04-30 Immunogen, Inc. Izboljšana metoda za aciliranje majtanzinola
CA2886993A1 (en) 2012-10-04 2014-04-10 Immunogen, Inc. Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
SI2943511T1 (sl) 2013-01-14 2020-01-31 Xencor, Inc. Novi heterodimerni proteini
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN103933575B (zh) 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
ES2885696T3 (es) 2013-03-15 2021-12-15 Xencor Inc Proteínas heterodiméricas
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
PT3122781T (pt) 2014-03-28 2020-03-05 Xencor Inc Anticorpos biespecíficos que se ligam a cd38 e cd3
CN104974252B (zh) * 2014-04-01 2020-04-24 三生国健药业（上海）股份有限公司 一种抑制肿瘤生长的抗体-小分子药物偶联物及其制备方法和用途
EP3160518A4 (en) 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
SG11201701328XA (en) 2014-09-02 2017-03-30 Immunogen Inc Methods for formulating antibody drug conjugate compositions
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
HUE051002T2 (hu) 2014-09-03 2021-01-28 Immunogen Inc Citotoxikus benzodiazepin származékok
AU2015353409B2 (en) 2014-11-26 2019-05-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TN2017000222A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN106279352B (zh) 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
CN106243127B (zh) 2015-06-09 2021-01-26 凯惠科技发展(上海)有限公司 抗体药物偶联物、中间体、制备方法、药物组合物及应用
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
HUE068801T2 (hu) 2016-06-14 2025-01-28 Xencor Inc Bispecifikus kontrollpont-gátló antitestek
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
CA3039930A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
JP2019535829A (ja) 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
CN116785450A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
JP2020529832A (ja) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
KR102722731B1 (ko) 2017-12-19 2024-10-25 젠코어 인코포레이티드 조작된 il-2 fc 융합 단백질
JP2021508714A (ja) 2017-12-28 2021-03-11 イミュノジェン・インコーポレーテッド ベンゾジアゼピン誘導体
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CR20210047A (es) 2018-07-02 2021-05-21 Amgen Inc Proteína de unión al antígeno anti-steap1
JP2021533102A (ja) 2018-07-27 2021-12-02 プロメガ コーポレイションPromega Corporation キノン含有複合体
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
MX2021010390A (es) 2019-03-01 2021-11-17 Xencor Inc Anticuerpos heterodimericos que se unen a enpp3 y cd3.
HUE061695T2 (hu) * 2019-04-18 2023-08-28 Indena Spa Diaszteroszelektív eljárás tiol-vagy diszulfid-tartalmú maytansinoid-észterek elõállítására és köztitermékeik
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
CA3146385A1 (en) 2019-07-10 2021-01-14 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
PE20220563A1 (es) 2019-07-10 2022-04-13 Cybrexa 2 Inc Conjugados peptidicos de citotoxinas como terapeuticos
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind CD3 and CLDN6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
EP4433170A1 (en) 2021-11-18 2024-09-25 Oxford BioTherapeutics Ltd Pharmaceutical combinations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1005569A2 (en) 1997-08-01 2000-06-07 MorphoSys AG Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
EP1229934B1 (en) * 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
JP5224632B2 (ja) * 2001-09-05 2013-07-03 ジェネンテック， インコーポレイテッド 細胞増殖異常に伴う疾患に関連するポリペプチド抗原の同定方法及びそのような疾患の治療に有効な組成物
CN102940889A (zh) * 2003-05-14 2013-02-27 伊缪诺金公司 药物缀合物组合物
AU2004240541B2 (en) * 2003-05-20 2009-08-20 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
DK1660513T5 (da) * 2003-07-21 2011-07-18 Immunogen Inc CA6 antigen-specifikt, cytotoksisk konjugat og fremgangsmåder til anvendelse heraf

Also Published As

Publication number Publication date
HK1116777A1 (en) 2009-01-02
IL231810A (en) 2016-02-29
IL241211B (en) 2019-09-26
HRP20210464T1 (hr) 2021-05-14
EP3031810B1 (en) 2019-03-06
CN1956722A (zh) 2007-05-02
SI1651162T1 (sl) 2016-02-29
IL223297A0 (en) 2012-12-31
BRPI0419348B8 (pt) 2021-05-25
HUE028314T2 (hu) 2016-12-28
MXPA05011811A (es) 2006-02-17
IL241211A0 (en) 2015-11-30
EA200501836A1 (ru) 2006-08-25
IL213876A (en) 2013-12-31
JP5563673B2 (ja) 2014-07-30
SI3524611T1 (sl) 2021-05-31
IL213876A0 (en) 2011-07-31
BRPI0419348B1 (pt) 2018-10-16
CN101186613A (zh) 2008-05-28
IL171170A (en) 2015-09-24
BRPI0410748A (pt) 2006-06-27
CR20170291A (es) 2017-07-27
CY1117161T1 (el) 2017-04-05
PL3524611T3 (pl) 2021-06-14
JP2013082733A (ja) 2013-05-09
NO20056039L (no) 2006-02-20
BRPI0410748B1 (pt) 2019-02-19
PL1651162T3 (pl) 2016-04-29
AU2004240541A1 (en) 2004-12-02
PT3524611T (pt) 2021-04-01
NZ542695A (en) 2009-04-30
LT3524611T (lt) 2021-04-12
EP1651162A4 (en) 2010-06-30
MX370281B (es) 2019-12-09
ES2863498T3 (es) 2021-10-11
ECSP056149A (es) 2006-10-17
IL238894A0 (en) 2015-06-30
IL238894A (en) 2017-06-29
WO2004103272A3 (en) 2006-11-23
CY1124278T1 (el) 2021-10-29
EP1651162A2 (en) 2006-05-03
ES2559670T3 (es) 2016-02-15
KR101145506B1 (ko) 2012-05-15
DK1651162T3 (en) 2016-02-01
KR20060003120A (ko) 2006-01-09
WO2004103272A2 (en) 2004-12-02
CL2012000651A1 (es) 2012-10-19
EP3031810A1 (en) 2016-06-15
EP1651162B1 (en) 2015-10-21
HRP20160046T1 (hr) 2016-02-12
EP3851126A1 (en) 2021-07-21
JP5208420B2 (ja) 2013-06-12
PT1651162E (pt) 2016-02-22
EP3524611B1 (en) 2020-12-30
JP2007514646A (ja) 2007-06-07
CN101186613B (zh) 2014-09-17
CA2525130C (en) 2014-04-15
EP3524611A1 (en) 2019-08-14
IL231810A0 (en) 2014-05-28
ZA200507845B (en) 2007-03-28
NO339597B1 (no) 2017-01-09
MX340862B (es) 2016-07-28
EA010909B1 (ru) 2008-12-30
CA2525130A1 (en) 2004-12-02
IL223297A (en) 2014-04-30
AU2004240541B2 (en) 2009-08-20
BRPI0410748B8 (pt) 2021-05-25
CO5660276A2 (es) 2006-07-31
DK3524611T3 (da) 2021-04-06

Similar Documents

Publication Publication Date Title
HK1116777A1 (en) Improved cytotoxic agents comprising new maytansinoids
GB0303910D0 (en) Therapeutic agents
EP1614386A4 (en) ECHOGRAPHIC APPARATUS
EP1676582A4 (en) AGENT CONTROLLING CORONAVIRUS
GB0315259D0 (en) Use
GB0305989D0 (en) Agent
GB0303683D0 (en) Antimicrobial agents
GB0301350D0 (en) Therapeutic agents
GB0316889D0 (en) Pharmaceutical agents
GB0302741D0 (en) Use
GB0313511D0 (en) Combination
EP1709976A4 (en) EMT-INDUCING MEDIUM
GB0423316D0 (en) Opthalmoscope
GB0316757D0 (en) Use
IL164811A0 (en) Vitamin-targeted inaging agents
GB0303623D0 (en) Muscarinic agents
GB0306445D0 (en) Conjugate
GB0316208D0 (en) New cytotoxic steriod compounds
GB0323861D0 (en) Use
GB0325976D0 (en) Use
GB0300295D0 (en) Use
GB0310755D0 (en) Use
GB0310754D0 (en) Use
GB0325977D0 (en) Use
GB0323744D0 (en) Nappy